Confirmatory diagnosis and successive chemotherapeutic treatments of metastatic skeletal <i>EWSR1::NFATC2</i> sarcoma: A case report
Tetsuya Urasaki(Japanese Foundation For Cancer Research), Shunji Takahashi(Japanese Foundation For Cancer Research), Yasuyoshi Sato(The Cancer Institute Hospital), Kyoko Yamashita, Junichi Tomomatsu(The Cancer Institute Hospital), Keiko Hayakawa(Cancer Institute (WIA)), Ryosuke Oki(Tokushima University), Masanori Saito(Japanese Foundation For Cancer Research), Naoki Fukuda(The Cancer Institute Hospital), Kengo Takeuchi(Japanese Foundation For Cancer Research), Makiko Ono(The Cancer Institute Hospital), Seiichi Matsumoto(Fukuda Denshi (Japan)), Taisuke Tanizawa(Japanese Foundation For Cancer Research), Akihiro Ohmoto(Japanese Foundation For Cancer Research), Kenji Nakano(Japanese Foundation For Cancer Research), Xiaofei Wang(Louisiana State University Health Sciences Center New Orleans), Keisuke Ae(The Cancer Institute Hospital), Hirotaka Suto(Japanese Foundation For Cancer Research), Yuki Togashi(Japanese Foundation For Cancer Research), Takehiro Nakao(Japanese Foundation For Cancer Research)
Cited by 5
Related Papers
Clear Cell Sarcoma of Soft Tissue
|The American Journal of Surgical Pathology|2008|283
Cancer-secreted hsa-miR-940 induces an osteoblastic phenotype in the bone metastatic microenvironment via targeting ARHGAP1 and FAM134A
|Proceedings of the National Academy of Sciences|2018|264
Carbon Ion Radiation Therapy for Unresectable Sacral Chordoma: An Analysis of 188 Cases
|International Journal of Radiation Oncology*Biology*Physics|2016|182
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study
|Annals of Oncology|2022|148
Uterine adenomyosis is an oligoclonal disorder associated with KRAS mutations
|Nature Communications|2019|137